CACNG1

Summary

CACNG1 (calcium voltage-gated channel auxiliary subunit gamma 1, HGNC:1405) is a protein-coding gene on chromosome 17q24.2, encoding Voltage-dependent calcium channel gamma-1 subunit (Q06432). Regulatory subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents in skeletal muscle.

Voltage-dependent calcium channels are composed of five subunits. The protein encoded by this gene represents one of these subunits, gamma, and is one of two known gamma subunit proteins. This particular gamma subunit is part of skeletal muscle 1,4-dihydropyridine-sensitive calcium channels and is an integral membrane protein that plays a role in excitation-contraction coupling. This gene is part of a functionally diverse eight-member protein subfamily of the PMP-22/EMP/MP20 family and is located in a cluster with two family members that function as transmembrane AMPA receptor regulatory proteins (TARPs).

Source: NCBI Gene 786 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 46 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000727

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1405
Approved symbol	CACNG1
Name	calcium voltage-gated channel auxiliary subunit gamma 1
Location	17q24.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000108878
Ensembl biotype	protein_coding
OMIM	114209
Entrez	786

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000226021, ENST00000958687

RefSeq mRNA: 1 — MANE Select: NM_000727 NM_000727

CCDS: CCDS11668

Canonical transcript exons

ENST00000226021 — 4 exons

Exon	Start	End
ENSE00000742735	67053996	67054070
ENSE00000742738	67055103	67055240
ENSE00000837191	67044554	67044889
ENSE00000837192	67056045	67056797

Expression profiles

Bgee: expression breadth ubiquitous, 124 present calls, max score 98.26.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.1024 / max 685.4211, expressed in 85 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
162325	1.6426	76
162324	0.3270	53
162326	0.0522	20
162323	0.0347	19
162327	0.0318	16
162328	0.0141	4

Top tissues by expression

273 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gastrocnemius	UBERON:0001388	98.26	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.78	gold quality
triceps brachii	UBERON:0001509	96.35	gold quality
muscle of leg	UBERON:0001383	96.01	gold quality
muscle organ	UBERON:0001630	95.83	gold quality
quadriceps femoris	UBERON:0001377	95.60	gold quality
vastus lateralis	UBERON:0001379	95.56	gold quality
skeletal muscle tissue	UBERON:0001134	95.25	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	95.20	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	95.08	gold quality
biceps brachii	UBERON:0001507	94.24	gold quality
gluteal muscle	UBERON:0002000	93.29	gold quality
diaphragm	UBERON:0001103	92.80	gold quality
deltoid	UBERON:0001476	92.71	gold quality
tibialis anterior	UBERON:0001385	91.38	silver quality
muscle tissue	UBERON:0002385	87.54	gold quality
tongue squamous epithelium	UBERON:0006919	75.71	gold quality
hair follicle	UBERON:0002073	73.13	gold quality
body of tongue	UBERON:0011876	70.49	gold quality
olfactory bulb	UBERON:0002264	70.24	gold quality
type B pancreatic cell	CL:0000169	70.18	gold quality
oocyte	CL:0000023	69.21	gold quality
jejunum	UBERON:0002115	68.80	silver quality
orbitofrontal cortex	UBERON:0004167	67.09	gold quality
epithelial cell of pancreas	CL:0000083	65.56	gold quality
tongue	UBERON:0001723	65.45	gold quality
Brodmann (1909) area 46	UBERON:0006483	65.07	gold quality
cervix squamous epithelium	UBERON:0006922	65.06	gold quality
nasal cavity epithelium	UBERON:0005384	64.91	gold quality
cartilage tissue	UBERON:0002418	64.04	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.55

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

21 targeting CACNG1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-4470	99.66	69.35	1767
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-4489	99.50	65.56	785
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-374A-3P	98.87	67.82	1531
HSA-MIR-6761-5P	98.71	68.03	1504
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-3130-5P	98.14	66.00	711
HSA-MIR-9851-5P	97.57	67.49	1067
HSA-MIR-4482-5P	97.53	65.68	598

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cacng1a	ENSDARG00000008772
danio_rerio	cacng1b	ENSDARG00000052360
mus_musculus	Cacng1	ENSMUSG00000020722
rattus_norvegicus	Cacng1	ENSRNOG00000003245

Paralogs (1): CACNG6 (ENSG00000130433)

Protein

Protein identifiers

Voltage-dependent calcium channel gamma-1 subunit — Q06432 (reviewed: Q06432)

Alternative names: Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma

All UniProt accessions (1): Q06432

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents in skeletal muscle. Regulates channel inactivation kinetics.

Subunit / interactions. Component of a calcium channel complex consisting of a pore-forming alpha subunit (CACNA1S) and the ancillary subunits CACNB1 or CACNB2, CACNG1 and CACNA2D1. The channel complex contains alpha, beta, gamma and delta subunits in a 1:1:1:1 ratio, i.e. it contains either CACNB1 or CACNB2.

Subcellular location. Cell membrane. Sarcolemma.

Tissue specificity. Skeletal muscle.

Post-translational modifications. N-glycosylated.

Similarity. Belongs to the PMP-22/EMP/MP20 family. CACNG subfamily.

RefSeq proteins (1): NP_000718* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004031	PMP22/EMP/MP20/Claudin	Family
IPR005421	VDCC_g1su	Family
IPR008368	VDCC_gsu	Family

Pfam: PF13903

UniProt features (14 total): topological domain 5, transmembrane region 4, glycosylation site 2, chain 1, disulfide bond 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q06432-F1	76.28	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 57–80

Glycosylation sites (2): 43, 79

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 120 (showing top): KEGG_MAPK_SIGNALING_PATHWAY, MODULE_64, MODULE_329, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_MUSCLE_CONTRACTION, CAGCAGG_MIR370, GOBP_REGULATION_OF_MUSCLE_CONTRACTION, GOBP_MUSCLE_CONTRACTION, GOBP_REGULATION_OF_CALCIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_SARCOPLASMIC_RETICULUM_CALCIUM_ION_TRANSPORT, GOBP_REGULATION_OF_SYSTEM_PROCESS, GOBP_MUSCLE_SYSTEM_PROCESS, MODULE_175, LEE_AGING_CEREBELLUM_DN, GOBP_REGULATION_OF_TRANSPORT

GO Biological Process (8): positive regulation of muscle contraction (GO:0045933), establishment of localization in cell (GO:0051649), sarcoplasmic reticulum calcium ion transport (GO:0070296), calcium ion transmembrane transport (GO:0070588), regulation of calcium ion transmembrane transport via high voltage-gated calcium channel (GO:1902514), monoatomic ion transport (GO:0006811), calcium ion transport (GO:0006816), monoatomic ion transmembrane transport (GO:0034220)

GO Molecular Function (4): voltage-gated calcium channel activity (GO:0005245), calcium channel regulator activity (GO:0005246), calcium channel activity (GO:0005262), protein binding (GO:0005515)

GO Cellular Component (7): plasma membrane (GO:0005886), T-tubule (GO:0030315), sarcolemma (GO:0042383), L-type voltage-gated calcium channel complex (GO:1990454), voltage-gated calcium channel complex (GO:0005891), membrane (GO:0016020), monoatomic ion channel complex (GO:0034702)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
calcium ion transport	2
calcium channel activity	2
cellular anatomical structure	2
muscle contraction	1
regulation of muscle contraction	1
positive regulation of multicellular organismal process	1
establishment of localization	1
cellular localization	1
monoatomic cation transmembrane transport	1
calcium ion transmembrane transport via high voltage-gated calcium channel	1
regulation of calcium ion transmembrane transport	1
transport	1
metal ion transport	1
monoatomic ion transport	1
transmembrane transport	1
voltage-gated monoatomic cation channel activity	1
ion channel regulator activity	1
monoatomic cation channel activity	1
calcium ion transmembrane transporter activity	1
binding	1
membrane	1
cell periphery	1
sarcolemma	1
plasma membrane	1
voltage-gated calcium channel complex	1
T-tubule	1
calcium channel complex	1
plasma membrane protein complex	1
transmembrane transporter complex	1

Protein interactions and networks

STRING

1044 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CACNG1	CACNB1	Q02641	971
CACNG1	CACNG4	Q9UBN1	952
CACNG1	CACNA2D1	P54289	939
CACNG1	CACNA1D	Q01668	935
CACNG1	CACNG7	P62955	917
CACNG1	CACNG5	Q9UF02	916
CACNG1	CACNG3	O60359	914
CACNG1	CACNG8	Q8WXS5	891
CACNG1	CACNG2	Q9Y698	871
CACNG1	CACNA1S	Q13698	842
CACNG1	CACNA2D2	Q9NY47	816
CACNG1	CACNA2D3	Q8IZS8	713
CACNG1	CACNA2D4	Q7Z3S7	699
CACNG1	SCN4A	P35499	670
CACNG1	CACNA1A	P78510	615

IntAct

53 interactions, top by confidence:

A	B	Type	Score
	CACNG1	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	BIK	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	REEP4	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	FNDC9	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	ERVFRD-1	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	HSD17B13	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	VAPA	psi-mi:“MI:0915”(physical association)	0.560
ERVFRD-1	CACNG1	psi-mi:“MI:0915”(physical association)	0.560
MUC1	CACNG1	psi-mi:“MI:0915”(physical association)	0.560
MGST3	CACNG1	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	THAP4	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	CPLX4	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	GPX8	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	ODF4	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	TMEM45B	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	TLCD4	psi-mi:“MI:0915”(physical association)	0.560
GAD2	CACNG1	psi-mi:“MI:0915”(physical association)	0.560
FFAR2	CACNG1	psi-mi:“MI:0915”(physical association)	0.560
CACNG1	TMEM120B	psi-mi:“MI:0914”(association)	0.350

BioGRID (43): VAPA (Two-hybrid), CACNG1 (Two-hybrid), CACNG1 (Synthetic Lethality), CACNG1 (Synthetic Lethality), CACNG1 (Two-hybrid), FFAR2 (Two-hybrid), GAD2 (Two-hybrid), MGST3 (Two-hybrid), TMEM45B (Two-hybrid), TMEM56 (Two-hybrid), GPX8 (Two-hybrid), CPLX4 (Two-hybrid), HSD17B13 (Two-hybrid), THAP4 (Two-hybrid), ODF4 (Two-hybrid)

ESM2 similar proteins: A0A1D5NY17, A4IF75, B2RVY9, B3SHH9, F6V1J6, O42281, O70578, P19518, P97707, Q06432, Q08CE6, Q08DE1, Q0D289, Q0V9E0, Q14714, Q2MJQ7, Q4R4Z3, Q4V922, Q5CZV0, Q5PRC1, Q5RDV7, Q5XGU1, Q62147, Q66IV3, Q68FV0, Q6AZD1, Q6P0C6, Q6R5J2, Q6ZP80, Q6ZUX7, Q7ZZL8, Q86WI0, Q8BGA2, Q8NBL3, Q8VHW3, Q8VHW4, Q8VHW7, Q8VHW8, Q91Y55, Q925N4

Diamond homologs: O70578, P19518, P97707, Q06432, Q08DE1, Q2MJQ7, Q8VHW3, Q8VHW7, Q9BXT2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

46 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

512 predictions. Top by Δscore:

Variant	Effect	Δscore
17:67044886:GGGG:G	donor_gain	1.0000
17:67044887:G:GT	donor_gain	1.0000
17:67044887:GGG:G	donor_gain	1.0000
17:67044888:GG:G	donor_gain	1.0000
17:67044888:GGG:G	donor_gain	1.0000
17:67044889:GG:G	donor_gain	1.0000
17:67044890:G:GA	donor_loss	1.0000
17:67053994:A:AG	acceptor_gain	1.0000
17:67053995:G:GG	acceptor_gain	1.0000
17:67053995:GA:G	acceptor_gain	1.0000
17:67053995:GAGAA:G	acceptor_gain	1.0000
17:67054066:GAAGG:G	donor_gain	1.0000
17:67054069:GG:G	donor_gain	1.0000
17:67054070:GG:G	donor_gain	1.0000
17:67056039:CCCCA:C	acceptor_loss	1.0000
17:67056040:CCCAG:C	acceptor_loss	1.0000
17:67056041:CCA:C	acceptor_loss	1.0000
17:67056044:G:GC	acceptor_loss	1.0000
17:67044890:G:GG	donor_gain	0.9900
17:67053990:TTGCA:T	acceptor_loss	0.9900
17:67053991:TGCA:T	acceptor_loss	0.9900
17:67053992:GCA:G	acceptor_loss	0.9900
17:67053993:CA:C	acceptor_loss	0.9900
17:67053993:CAG:C	acceptor_gain	0.9900
17:67053994:A:AT	acceptor_loss	0.9900
17:67053994:AGA:A	acceptor_gain	0.9900
17:67053995:GAG:G	acceptor_gain	0.9900
17:67053995:GAGA:G	acceptor_gain	0.9900
17:67054067:AAGGG:A	donor_loss	0.9900
17:67054069:GGGTG:G	donor_loss	0.9900

AlphaMissense

1465 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:67054014:T:G	F83C	0.995
17:67055138:A:C	S114R	0.995
17:67055140:C:A	S114R	0.995
17:67055140:C:G	S114R	0.995
17:67044820:T:A	W54R	0.994
17:67044820:T:C	W54R	0.994
17:67044754:T:A	W32R	0.993
17:67044754:T:C	W32R	0.993
17:67044822:G:C	W54C	0.993
17:67044822:G:T	W54C	0.993
17:67055240:G:C	G148R	0.993
17:67056050:T:C	C150R	0.992
17:67044824:G:C	R55P	0.991
17:67054013:T:C	F83L	0.991
17:67054015:C:A	F83L	0.991
17:67054015:C:G	F83L	0.991
17:67055159:G:C	G121R	0.991
17:67044715:G:C	G19R	0.990
17:67044815:G:A	G52D	0.990
17:67054004:T:A	C80S	0.990
17:67054005:G:C	C80S	0.990
17:67044756:G:C	W32C	0.989
17:67044756:G:T	W32C	0.989
17:67044829:T:A	C57S	0.989
17:67044830:G:A	C57Y	0.989
17:67044830:G:C	C57S	0.989
17:67055108:A:C	S104R	0.989
17:67055110:C:A	S104R	0.989
17:67055110:C:G	S104R	0.989
17:67044814:G:C	G52R	0.988

dbSNP variants (sampled 300 via entrez): RS1000348210 (17:67054376 C>T), RS1000676404 (17:67049264 C>T), RS1000944843 (17:67044208 C>T), RS1000956594 (17:67055331 G>A,C,T), RS1001113253 (17:67049921 T>G), RS1001250993 (17:67056350 C>A,T), RS1001664931 (17:67050785 C>A), RS1001780903 (17:67051067 G>A), RS1001826344 (17:67051517 T>C), RS1001981837 (17:67045044 T>C), RS1002248382 (17:67046643 A>G), RS1002465428 (17:67045832 C>G,T), RS1003360737 (17:67053690 G>A), RS1003379060 (17:67054267 G>A), RS1003468908 (17:67047099 T>C)

Disease associations

OMIM: gene MIM:114209 | disease phenotypes: MIM:145600

GenCC curated gene-disease

Mondo (1): malignant hyperthermia, susceptibility to, 1 (MONDO:0007783)

Orphanet (1): Malignant hyperthermia of anesthesia (Orphanet:423)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009723_92	Vertical cup-disc ratio (adjusted for vertical disc diameter)	1.000000e-07
GCST009724_72	Vertical cup-disc ratio (multi-trait analysis)	7.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006939	cup-to-disc ratio measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C535694	Malignant hyperthermia susceptibility type 1 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2363032 (PROTEIN COMPLEX GROUP)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 67,947 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1428	NIMODIPINE	4	32,587
CHEMBL95	TACRINE	4	35,360

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

2 measured of 2 human assays (6 total across all organisms); most potent 2 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
SR 147778	KI	1000 nM
3,5-diamino-6-chloro-N-(diaminomethylene)pyrazinamide;hydrochloride	IC50	6630 nM

ChEMBL bioactivities

58 potent at pChembl≥5 of 75 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.82	IC50	1.5	nM	CHEMBL3891844
8.72	IC50	1.9	nM	CHEMBL3890624
8.62	IC50	2.4	nM	CHEMBL3973392
8.57	IC50	2.7	nM	CHEMBL3891844
8.52	IC50	3	nM	CHEMBL3919024
8.51	IC50	3.1	nM	CHEMBL3919898
8.35	IC50	4.5	nM	CHEMBL3965812
8.23	IC50	5.9	nM	CHEMBL3906126
8.22	IC50	6	nM	CHEMBL3890916
8.15	IC50	7	nM	CHEMBL3940577
8.14	IC50	7.2	nM	CHEMBL3969562
8.12	IC50	7.6	nM	CHEMBL3937280
8.12	IC50	7.6	nM	CHEMBL3965812
8.10	IC50	8	nM	CHEMBL3983323
8.05	IC50	9	nM	CHEMBL3942512
8.03	IC50	9.4	nM	CHEMBL3922498
8.01	IC50	9.7	nM	CHEMBL3897303
7.96	IC50	11	nM	CHEMBL3948329
7.92	IC50	12	nM	CHEMBL3898359
7.85	IC50	14	nM	CHEMBL3911369
7.85	IC50	14	nM	CHEMBL3913505
7.85	IC50	14	nM	CHEMBL3936725
7.82	IC50	15	nM	CHEMBL3984596
7.82	IC50	15	nM	CHEMBL3902376
7.67	IC50	21.5	nM	CHEMBL3952905
7.62	IC50	24	nM	CHEMBL3972896
7.58	IC50	26	nM	CHEMBL3889804
7.55	IC50	28	nM	CHEMBL3958844
7.55	IC50	28	nM	CHEMBL3973382
7.52	IC50	30	nM	CHEMBL3978200
7.52	IC50	30	nM	CHEMBL3985660
7.51	IC50	31	nM	CHEMBL3896861
7.51	IC50	31	nM	CHEMBL3951956
7.50	IC50	31.4	nM	CHEMBL3962403
7.44	IC50	36	nM	CHEMBL3953976
7.44	IC50	36	nM	CHEMBL3925140
7.41	IC50	39	nM	CHEMBL3900691
7.39	IC50	41	nM	CHEMBL3930781
7.30	IC50	50	nM	CHEMBL3921840
7.21	IC50	62	nM	CHEMBL3956991
7.17	IC50	67	nM	CHEMBL3965293
7.09	IC50	81	nM	CHEMBL3958264
7.07	IC50	85	nM	CHEMBL3964411
7.01	IC50	98.5	nM	CHEMBL3953031
6.40	IC50	400	nM	CHEMBL3974355
6.10	IC50	800	nM	CHEMBL3734797
5.75	IC50	1800	nM	CHEMBL4228929
5.66	IC50	2200	nM	CHEMBL4226021
5.52	IC50	3000	nM	CHEMBL4228209
5.52	IC50	3000	nM	CHEMBL4224773

PubChem BioAssay actives

13 with measured affinity, of 101 total; 13 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-tert-butyl-8-[[[(1S,2S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropanecarbonyl]amino]methyl]-5-[3-(trifluoromethoxy)phenyl]-3,4-dihydro-1H-isoquinoline-2-carboxamide	1262825: Inhibition of voltage-gated calcium channel (unknown origin)	ic50	0.8000	uM
5-methyl-1-[(2-nitrophenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	1.8000	uM
1-[(3-chlorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	2.2000	uM
5-methyl-1-[(3-nitrophenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.0000	uM
1-[(4-chlorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.0000	uM
1-benzyl-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.4000	uM
5-methyl-1-[(4-methylphenyl)methyl]-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	3.6000	uM
1-[(4-fluorophenyl)methyl]-5-methyl-3-(piperidin-1-ylmethyl)indole	1392176: Inhibition of KCl-induced cytosolic voltage gated calcium channel opening in human SH-SY5Y cells by Fluo-4 AM dye based fluorescence assay	ic50	4.8000	uM
N-heptyl-16,18-dioxo-17-azapentacyclo[6.6.5.02,7.09,14.015,19]nonadeca-2,4,6,9,11,13-hexaene-1-carboxamide	1612587: Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay	ic50	9.0000	uM
ethyl 5-amino-4-(3-methoxyphenyl)-2-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	9.0000	uM
ethyl 5-amino-4-(3,4-dimethoxyphenyl)-2-methyl-7,8,9,10-tetrahydro-6H-cyclohepta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	9.0000	uM
propan-2-yl 5-amino-2-methyl-4-phenyl-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	10.0000	uM
ethyl 5-amino-2-methyl-4-phenyl-6,7,8,9,10,11-hexahydrocycloocta[b][1,8]naphthyridine-3-carboxylate	1653244: Inhibition of VGCC (unknown origin)	ic50	10.0000	uM

CTD chemical–gene interactions

11 total (human), top 11 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
incobotulinumtoxinA	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Aspirin	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Niclosamide	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Rotenone	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	increases expression	1
Aflatoxin B1	increases methylation	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3737861	Binding	Inhibition of voltage-gated calcium channel (unknown origin)	Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_YA28	IDG-HEK293T-CACNG1-V5-OE	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.